Business & Economics

Research associate at Genmab, Cell culturing. Photo courtesy: 2020 Genmab/Tuala Hjarnø and Torkil Stavdal

AbbVie and Genmab Sign U.S. $ 3.9 Billion Development Agreement

Chicago-based AbbVie and Genmab, headquartered in Copenhagen, Denmark, have entered into a broad oncology development program in which the...
Featured Image: MabPlex Building, Yantai, Shandong, China. Courtesy: © 2017 MabPlex. Used with permission.

MabPlex International Secures Series B Financing

MabPlex International, a Contract Development and Manufacturing Organization (CDMO) based in Yantai, the Shandong Peninsula in northeastern Shandong province,...

ImmunoGen Initiates Pivotal Trial Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Biotech company ImmunoGen, leveraging the targeting ability of antibodies to deliver cytotoxic drugs directly to cancer cells by developing...
Ajinomoto Bio-Pharma Services has established a high-containment bioconjugate manufacturing facility for the production and fill and finish of Highly Potent Active Pharmaceutical Intermediates (HPAPI) and Antibody Drug Conjugates (ADC). The facility, developed by SKAN AG, has been designed for safe handling and manipulation of very low OEL compounds (down to 1 ng/m3) while maintaining aseptic conditions and cGMP compliance. Photo courtesy: © 2020 Ajinomoto Bio-Pharma.

Trio Pharmaceuticals and Ajinomoto Ink Agreement to Develop First-in-class Dual Functionality ADC

Patients being treated for cancer may often benefit from a combination of systemic cancer chemotherapies. The rationale for the...

Everest Medicines’ Licensing Partner Immunomedics Receives FDA Accelerated Approval for Sacituzumab Govitecan for the...

Everest Medicines' U.S.-based licensing partner Immunomedics earlier today confirmed that the U.S. Food and Drug Administration (FDA) has approved...
Featured image: An aerial view of the Yangtze River Delta/Shanghai in the southern Jiangsu province and northern Zhejiang province. Photo Courtecy: 2015 - 2020 © VCG/Gettyimages. Used with permission.

Everest Medicines to Initiate a Registration Study in China for Sacituzumab Govitecan in mTNBC

China-based Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative products, address critical unmet medical needs for...

FDA Grants Accelerated Approval for Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan* (Trodelvy™; Immunomedics) for the treatment of adult patients...
Featured Image Courtesy: Byondis Biopharmaceuticals (previously Synthon Biopharmaceuticals, Nijmegen, The Netherlands.

Netherlands Based Precision Medicines Developer Relaunches as Byondis

Netherlands-based Synthon Biopharmaceuticals, a biopharmaceutical research, and development company creating innovative precision medicines including the anti-HER2 investigational antibody-drug conjugate...

Mersana Reports Updated Data from the XMT-1536 Phase I Dose Escalation Study; Raises U.S....

Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers...

Potential Accelerated Approval for Enfortumab Vedotin in Combination with Pembrolizumab as First-Line Treatment for...

Updated data from the phase Ib/II multicohort EV-103 trial (NCT03288545; also known as KEYNOTE-869) of enfortumab vedotin* (Padcev™; Seattle...